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Endothelins are a family of peptide mediators that have a number of biological properties, including the ability to
act as bronchoconstrictors and vasoconstrictors of isolated airways and vessels. Endothelin-1 (ET-1) is the more
potent peptide compared with the other two peptides of the family.
To examine a possible involvement of ET-1 in the pathogenesis of asthma, we measured arterial ET-1 levels in 11
patients with atopic asthma during attack and during remission, and in 11 healthy control subjects. We also
performed fiberoptic bonchoscopy and bronchoalveolar lavage (BAL) to measure ET-1 levels in the 11 asthmatic
patients during remission, and in the 11 healthy control subjects. ET-1 concentrations in arterial blood and in BAL
were measured by a radioimmunoassay method.
Arterial ET-1 levels were very significantly higher in asthma attack (3?67+0?51 pgml71) and in asthma remission
(2?65+10?62 pgml71) compared with those of the healthy controls (1?37+0?14 pgml71) (P50?001). Arterial ET-1
levels were also very significantly higher during asthma attack compared with those in asthma remission
(P50?001). BAL ET-1 levels were significantly higher in asthma remission (0?73+0?53 pmol g71) compared with
those of the healthy controls (0?16+0?02 pmol g71) (P50?05). No correlation was observed between arterial and
BAL ET-1 levels, PaO2 and peak expiratory flow rate (PEFR).
These data are consistent with the hypothesis that ET-1 contributes to the pathophysiology of asthma. However,
it is likely that the true importance of this vasoconstrictor peptide will only be revealed by pharmacological studies
with specific receptor antagonists.
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Asthma is an inflammatory disorder of the airways
characterized by bronchoconstriction and bronchial hyper-
reactivity. Airway wall thickening due to oedema and
structural remodelling is likely to contribute to both these
abnormalities and may be explained in part by the local
generation and release of ET-1 in the airways (1).
ET-1 is a vasoactive 21 amino acid peptide produced by
human bronchial epithelial cells (2), vascular endothelial
cells (3) and inflammatory cells such as macrophages (4),
mast cells (5) and alveolar epithelial cells (6). ET-1 produces
prolonged and potent bronchoconstriction in asthma (7)
and has mitogenic properties, with animal studies indicat-
ing a role in the proliferation of cultured airway smooth
muscle cells (8) and airway epithelial cells (9). ET-1 also
acts as a co-mitogen with a number of other growth factors,
and induces the expression of pro-inflammatory and pro-Received 8 February 2000 and accepted in revised form 30 May
2000.
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(TNFa) (10) and fibronectin (11).
Previous studies have shown that hypoxia stimulates ET-
1 secretion from endothelial cells (12,13). Another study
demonstrated that pulmonary alveolar hypoxia increases
lung and plasma ET-1 levels in conscious experimental
animals and that this peptide increase is parallel to the
severity of arterial hypoxaemia (14).
The objectives of the study were to examine (i) the
arterial ET-1 concentration of asthmatic patients during
severe attack and in remission and (ii) the BAL ET-1
concentration of asthmatic patients in remission. We
compared the results with the arterial and BAL ET-1
concentrations of normal subjects to establish a possible
role of ET-1 in the pathogenesis of asthma.
Material and methods
Eleven healthy control subjects (seven males, four females)
with mean age 22?27+2?97 years and 11 asthmatic patients
(six males, five females) with mean age 21?90+3?80 years
were studied. The study was approved by the University
Hospital of Patras Medical School Ethical Committee and# 2000 HARCOURT PUBLISHERS LTD
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informed consent.
All the asthmatic patients were admitted to our hospital
between February 1995 and August 1998 with a severe
asthma attack. They received the appropriate therapy with
2-agonists, ipratropium bromide, corticosteroids and
theophyllines during the exacerbation.
The same asthmatic patients (in remission) and the
healthy control subjects presented 1–2 weeks before
bronchoscopy for skin-prick testing and measurement of
their bronchial reactivity by a modification of the method
of Chai et al. (15). For this visit, patients with asthma were
asked to withhold short-acting 2-agonist therapy and
inhaled corticosteroids for a minimum of 6 h. None of the
patients was receiving systemic corticosteroids. The atopic
status was determined using the following common
aeroallergens; mixed grass pollens, dermatophagoides,
pterenyssinus, mixed leathers, cat fur and dog hair. The
11 normal subjects (two atopic) had no history of
symptoms suggestive of asthma or rhinitis, were on no
regular medication and had normal spirometry
(FEV1495% of predicted, PEFR 495% of predicted)
and normal bronchial reactivity (cumulative PC20 methyl-
choline 4 25mgml71). The patients with asthma were all
atopic with a wheal reaction of diameter 2mm or greater in
response to one or more of the above aeroallergens in the
presence of negative saline and positive histamine controls.
Their mean PC20 methylcholine was 0?56+0?27mgml
71.
The clinical and physiological details of the subjects
(controls and patients) are summarized in Tables 1 and 2.
Arterial blood for measuring partial pressure of oxygen
(PaO2) and ET-1 concentration was collected from the
asthmatic patients during the attack (on admission to
the hospital) and during the remission 1–2 weeks before
bronchoscopy. Arterial blood was also collected from the
normal subjects. PaO2 was measured in a blood gas analyser
Eschweiler system C-100 (West Germany).
Arterial blood for measuring ET-1 was collected in
chilled vacutainers containing disodium dihydrogen ethy-
lenediamine tetra-acetate dihydrate, and then centrifuged at
30006g for 20min to obtain plasma. The plasma was
aliquoted and frozen at7808C until analysis. Arterial ET-1
levels were measured by radioimmunoassay (RIA). Briefly,
the samples were extracted using C18 cartidges (SepPak,
Waters, Missisauga, Ontario, Canada) activated by metha-
nol, and 8M urea and water and then eluted by 100%
methanol. Samples and standards (synthetic endothelin-1;
Peptide Institute, Osaka, Japan) were reconstituted in assay
buffer and incubated with rabbit antiendothelin-1 anti-
serum (Peninsula Laboratories, Belmont, CA, U.S.A.) at
48C for 24 h. This was followed by the addition of 125I-
labelled ET-1 (Amersham International Amersham, U.K.)
and a second 24 h incubation. Bound and free radioactivity
was separated by the second antibody method, and the
gamma emission for the precipitate of antibody ET-1
complexes was counted using a gamma counter. The intra-
and inter-assay coecients of variation were 10% and 13%,
respectively.
Fiberoptic bronchoscopy was undertaken in accordance
with the current published guidelines (16). Briefly, subjectsreceived premedication with atropine (0?5mg i.m.) and a
combination of nebulized salbutamol (2?5mg) and ipra-
tropium bromide (0?5mg). Local anaesthesia of the upper
and lower airways was achieved by topical application of
4% and 1% lignocaine. Twenty-eight percent oxygen was
administered continuously with a Ventouri face mask and
the arterial O2 saturation was monitored throughout the
procedure using a pulse oximeter (AMI system 7300, AMI,
Broken Arrow, OK, U.S.A.). Oxygen administration
during bronchoscopy is in accordance with the current
published guidelines (16) as the procedure causes a fall of
PaO2 10–20mmHg. A Pentax FB 19TX fibre optic
bronchoscope was introduced using the nasal route and
was wedged in a segmental bronchus of the right upper
lobe for BAL. Lavage was performed using 120ml of
prewarmed 0?9% sodium chloride solution as six 20ml
aliquots with recovery by means of gentle suction following
each aliquot. From the total sample of BAL fluid recovered
10ml was withdrawn and mixed with 0?2ml aprotin
(10 000Kallikrein unitsml71) (Bayer Ltd, Newbury, Berk-
shire, U.K.) in order to prevent degradation of ET by BAL
fluid proteases. The samples was then immediately frozen
and stored at 7808C before assay. BAL ET-1 concentra-
tion was measured by radioimmunoassay as described
previously.
All data were expressed as the mean value +SD. The
relation between several magnitudes were examined by
simple and multiple linear regression analysis. Differences
between the various groups were analysed using the one
way analysis of variance and student’s t-test. A P-value of
50?05 was considered to be statistically significant.
Results
The normal subjects had a significantly higher percent
predicted peak expiratory flow rate (PEFR) than the patients
with asthma both during attack (P50?0001) and during
remission (P50?05). Also the normal subjects had signifi-
cantly higher PaO2 than the patients with asthma both
during attack (P50?001) and during remission (P50?001).
All the normal subjects had a negative metacholine challenge
test. All the asthmatic patients had a positive metacholine
challenge test. The mean value+SD of the above magnitudes
are summarized in Tables 1, 2 and 3.
The normal subjects had significantly lower arterial ET-1
concentration (1?37+0?14 pgml71) than the asthmatic
patients both during attack (3?67+0?51 pgml71,
P50?001) and during remission (2?65+0?62 pgml71,
P50?001). Arterial ET-1 concentration was significantly
higher in asthma attack (3?67+0?5 pgml71) than in asthma
remission (2?65+0?62 pgml71, P50?001) (Figure 1).
The volume of BAL fluid recovered did not differ
significantly between normal subjects and asthmatic pa-
tients (P50?05). The proportions of the original 120ml
instilled were 53?8+9?1 % and 52?4+7?2 % respectively.
Table 4 presents the results for the differential cell counts.
In the asthmatic patients there was a significant increase in
the percentage of eosinophils (P50?02) and epithelial cells
(P50?003) when compared with the control subjects. The
TABLE 1. Clinical and physiological parameters of the examined controls
Controls Age Sex PEFR (% pred) HR RR RC20 (mgml
71) PaO2 mmHg
1 18 M 110 72 14 4 25?0 98?3
2 23 M 101 75 18 4 25?0 96?2
3 25 F 106 80 12 4 25?0 100?1
4 19 M 99 67 17 4 25?0 98?2
5 24 F 95 81 18 4 25?0 98?0
6 20 F 103 88 16 4 25?0 95?1
7 20 F 107 73 18 4 25?0 95?5
8 26 M 111 75 18 4 25?0 94?7
9 21 M 116 76 16 4 25?0 99?2
10 27 M 95 67 16 4 25?0 99?4
11 22 M 92 69 17 4 25?0 99?7
Mean+SD 22?27+2?97 103?18+7?58 74?81+6?38 16?36+1?91 97?66+121?97
PEFR: peak expiratory flow rate; HR: heart rate; RR: respiratory rate.
TABLE 2. Clinical and physiological parameters of patients during asthmatic attack
Controls Age Sex PEFR (% pred) HR RR PaO2 mmHg
1 19 F 48 125 30 58?3
2 25 M 45 136 33 59?8
3 21 M 50 138 31 46?7
4 23 M 51 128 35 39?7
5 18 F 46 140 30 57?5
6 19 F 42 135 37 60?1
7 26 M 48 170 35 48?2
8 28 M 45 140 32 52?3
9 26 M 43 131 32 57?3
10 18 F 47 135 40 58?1
11 18 F 40 140 40 58?8
Mean+SD 21?90+3?80 45?90+3?36 138+11?37 34?09+3?64 54?25+6?68
PEFR: peak expiratory flow rate; HR: heart rate; RR: respiratory rate.
TABLE 3. Spirometric values, PaO2 and metacholine test in patients with asthma, during remission
PEFR % pred PaO2 FEV1 FVC RC20 (mgml
71)
65 80?3 75 84 0?78
70 82?7 81 91 0?76
67 80?1 78 85 0?58
78 86?7 80 91 0?87
65 79?7 75 87 0?16
79 90?1 82 86 0?24
75 91?7 81 84 0?25
90 92?8 86 93 0?93
91 90?5 84 94 0?78
90 94?5 81 92 0?39
87 88?8 82 90 0?45
77?90+10?34 87?08+5?49 80?45+3?80 88?81+4?60 0?56+0?27
FVC: forced vital capacity; FEV1: forced expiratory volume in 1 sec.
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FIG. 1. Arterial endothelin-1 (ET-1) levels of the controls
and asthmatics during attack and remission. Controls
(&); asthma attach ( ); asthma remission ( ).
TABLE 4. Comparison of bronchoalveolar lavage fluid differential cell counts in normal subjects and in asthmatic patients
during remission expressed as median range
Macrophages
(%)
Lymphocytes
(%)
Neutrophils
(%)
Eosinophils
(%)
Epithelial cells
(%)
Normal subjects 82?3
(58?7–92?5)
6?3
(2?7–19?7)
4?8
(0–18?4)
0
(0–9?5)
5?7
(1?2–13?6)
Asthmatic patients during remission 85?9
(72?1–94?6)
6?5
(2?2–16?8)
0?4
(0–2?7)
1
(0?4–8?9)
2?6
(0?9–8?8)
FIG. 2. Broncho-alveolar lavage fluid endothelin-1 (ET-1)
levels of the controls (&) and asthmatics ( ) in remission.
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patients with asthma in remission (0?73+0?53 pgml71)
than in controls (0?16+0?02 pgml71) (P50?05) (Figure 2).
No statistically significant correlation was observed be-
tween arterial and BPAL ET-1 concentration, PaO2 and
PEFR.
Discussion
In this study we measured the arterial ET-1 concentration
in normal subjects and in patients with asthma on two
occasions: first during a severe asthma attack and second
during remission. We also measured BAL ET-1 concentra-
tion in normal subjects and in asthmatic patients during
remission.
The methodological diculties arising when using BAL
technique to investigate mediators in asthma have recentlybeen reviewed (17). Problems encountered include uncer-
tainty regarding the site of sampling, variable recovery of
BAL fluid and variable dilution of mediators. However,
despite these limitations, we have been able to demonstrate
that BAL fluid concentration of ET-1 is significantly higher
in subjects with asthma in remission, treated with bronch-
odilators and inhaled corticosteroids, than in normal
subjects. We have also demonstrated that arterial ET-1
concentration was significantly higher in asthmatic patients
both during attack and during remission compared with
normal subjects. These findings are consistent with the
hypothesis that this peptide mediator plays an important
role in the pathophysiological manifestations of asthma
(18).
No statistically significant correlation existed between
arterial ET-1 concentration and PEFR. ET-1 may con-
tribute to the pathogenesis of airflow obstruction in asthma
but this peptide does not play the main role. ET-1 has a
996 G. TRAKADA ET AL.number of prefibrotic properties and may thus be
implicated in the processes of myofibroblast proliferation
(19), sub-epithelial fibrosis (20) and airway wall thickening
(21) that occur in asthma. Also, no statistically significant
correlation existed between arterial ET-1 concentration and
PaO2. According to previous studies hypoxia stimulates ET-
1 secretion (12–14). Pro-inflammatory cytokines, such as
interleukin (IL)-1 (22) and tumour necrosis factor alpha
(TNFa) (10) also increase the expression of ET-1. There is
evidence that both of these cytokines are implicated in the
inflammatory response of asthma. Increased levels of IL-I
and TNFa are present in BAL fluid from symptomatic
subjects with asthma (23). An increased number of BAL
cells express mRNA for TNFa in subjects with asthma
compared with normal subjects (24) and increased number
of TNFa immunoreactive cells are identified in bronchial
biopsy specimens from patients with asthma compared with
the findings in normal airways (25). Thus, exposure of
bronchial epithelial and/or other cells in the airways to
these cytokines may account for the increased production
and release of ET-1 and not hypoxia.
According to out results, we conclude that ET-1 plays an
important role in the pathogenesis of asthma. Further
investigation is justified to clarify the exact role and the
possible interactions of ET-1 with other mediators in
asthma.
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